Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.92 USD
-0.02 (-2.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.90 -0.02 (-2.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 101 - 120 ( 144 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Results; ''806 Synthesis Protocol Established; Oral Formulation Complete; Time for the Clinic
Provider: H.C. Wainwright & Co., Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage at Neutral with a $1 price target.
Provider: Rodman & Renshaw, Co.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Ready, Set, Now Just Need Clinic-Ready Drugs to Go; Initiating Coverage at Neutral, $1 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of APTO to ROTH Capital Research, due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
The Light at the End of the "Hold" Tunnel Just Got Brighter
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
And the Clock Starts...Now; Formal Response Submitted to FDA
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; See Positioning as Favorable for ''253 Re-start
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Management Meetings Highlight Key Goals; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.